Gastrointestinal Malignancies in the Era of Precision Oncology: From Bench to Bedside and Back Again (Volume II)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 2249

Special Issue Editor


E-Mail Website
Guest Editor
1. Visiting Assistant Professor, Department of Pathology, Case Western Reserve University, Cleveland, OH 44106-1712, USA
2. Gastroenterology Division and Inflammatory Bowel Disease Center, Department of Internal Medicine, IRCCS Azienda Unità Sanitaria Locale di Reggio Emilia, 42122 Reggio Emilia, Italy
Interests: gastrointestinal pathology; inflammatory bowel diseases; gastrointestinal cancer; chronic inflammation; autoimmunity; autoinflammation and innate immunity; microbiome
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This collection is the second edition of a previous one, "Gastrointestinal Malignancies in the Era of Precision Oncology: From Bench to Bedside and Back Again" (https://www.mdpi.com/journal/cancers/special_issues/Gastrointestinal_Malignancies_Precision_Oncology_From_Bench_Bedside).

Physicians’ and researchers’ approaches to cancer are dramatically changing. Growing the knowledge of human genetics and finding insights into the links between chronic inflammation, immune system, microbiota and cancer development are some of the key steps contributing to advancing the era of precision oncology, as observed in recent years.

By using the same approach of precision medicine, and with the help of innovative techniques for data analysis including artificial intelligence (i.e., machine learning, deep learning, neural networks), a multidisciplinary team mainly composed of clinicians, surgeons, pathologists, radiologists, biostatisticians, geneticists and biologists surround the cancer patient in order to achieve molecular targeted and immune-based therapeutics across a variety of malignancies.

Gastrointestinal malignancies still have high tumor incidence and mortality rate worldwide, with a significant diversity in terms of prognosis and therapeutic response. There is an urgent need for the identification of suitable targets for tailor-made, personalized therapy in this field.

The aim of this Special Issue is to gather top experts covering all aspects of precision oncology for gastrointestinal cancer in 2021, from bench to bedside, and back again.

Dr. Alessandra Soriano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal cancer
  • precision medicine
  • immunity
  • gene expression profiling
  • biomarker
  • molecular targeted therapy
  • liquid biopsy
  • circulating tumor cells (CTCs)
  • immunotherapy
  • machine learning
  • organoids

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 3811 KiB  
Article
Efficacy of Different Oncolytic Vaccinia Virus Strains for the Treatment of Murine Peritoneal Mesothelioma
by Can Yurttas, Julia Beil, Susanne Berchtold, Irina Smirnow, Linus D. Kloker, Bence Sipos, Markus W. Löffler, Alfred Königsrainer, André L. Mihaljevic, Ulrich M. Lauer and Karolin Thiel
Cancers 2024, 16(2), 368; https://doi.org/10.3390/cancers16020368 - 15 Jan 2024
Viewed by 1926
Abstract
Effective treatment options for peritoneal surface malignancies (PSMs) are scarce. Oncolytic virotherapy with recombinant vaccinia viruses might constitute a novel treatment option for PSM. We aimed to identify the most effective oncolytic vaccinia virus strain in two murine mesothelioma cell lines and the [...] Read more.
Effective treatment options for peritoneal surface malignancies (PSMs) are scarce. Oncolytic virotherapy with recombinant vaccinia viruses might constitute a novel treatment option for PSM. We aimed to identify the most effective oncolytic vaccinia virus strain in two murine mesothelioma cell lines and the oncolytic potential in a murine model of peritoneal mesothelioma. Cell lines AB12 and AC29 were infected in vitro with vaccinia virus strains Lister (GLV-1h254), Western Reserve (GLV-0b347), and Copenhagen (GLV-4h463). The virus strain GLV-0b347 was shown most effective in vitro and was further investigated by intraperitoneal (i.p.) application to AB12 and AC29 mesothelioma-bearing mice. Feasibility, safety, and effectiveness of virotherapy were assessed by evaluating the peritoneal cancer index (PCI), virus detection in tumor tissues and ascites, virus growth curves, and comparison of overall survival. After i.p. injection of GLV-0b347, virus was detected in both tumor cells and ascites. In comparison to mock-treated mice, overall survival was significantly prolonged, ascites was less frequent and PCI values declined. However, effective treatment was only observed in animals with limited tumor burden at the time point of virus application. Nonetheless, intraperitoneal virotherapy with GLV-0b347 might constitute a novel therapeutic option for the treatment of peritoneal mesothelioma. Additional treatment modifications and combinational regimes will be investigated to further enhance treatment efficacy. Full article
Show Figures

Figure 1

Back to TopTop